{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:37:21Z","timestamp":1787852241113,"version":"build-2784847793"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T00:00:00Z","timestamp":1647302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) are widely used improving clinical outcomes in many cancer patients. However, they can induce serious consequences, like neurological immune-related adverse drug reactions (NirADRs). Although these are rare complications, they can be serious with important impact on patients\u2019 quality of life. Our purpose is to describe these adverse events observed in the European clinical practice context. We carried out a descriptive analysis of individual case safety reports (ICSRs) related to ICIs collected until February 7, 2020, in the European spontaneous reporting database, EudraVigilance, and reported nervous disorders as suspect adverse drug reactions (ADRs). NirADRs were classified according to the Medical Dictionary for Regulatory Activities (MedDRA). In order to identify a hypothetical different reporting probability of the NirADR types between the ICI classes, we carried out a disproportionality analysis. The reporting odds ratio (ROR) with 95% CI was computed comparing the different ICI classes to each other based on their pharmacological target [the cytotoxic T-lymphocyte antigen-4 (CTLA-4), the programmed death-1 (PD-1) or its ligand (PD-L1)]. Finally, we researched in the literature the hypothesized mechanisms, which could explain the onset of these ICI-related neurological complications. Overall, we found 4,875 cases describing 6,429 ICI-related suspected NirADRs. ICI-related neurotoxicities include a wide range of central and peripheral events. These were mainly related to anti-PD-1 agents and occurred in male patients (59%). Our analysis confirmed a gender difference of NirADRs. Twenty-three percent of the events (comprising myasthenia gravis, neuropathy peripheral, and cerebral infarction) had unfavorable fallouts, including fatal outcome (7%). Majority of the NirADRs were categorized as \u201cNeurological disorders NEC\u201d HLGTs MedDRA (2,076; 32%). In 1,094 cases (22%), more NirADRs overlapped with other neurologic complications. An interesting overlapping of myasthenia gravis with myositis or myocarditis emerged. From our disproportionality analysis, an increased reporting probability of peripheral neuropathies and headaches emerged with ipilimumab when compared to anti-PD-1 and anti-PD-L1 agents. However, neuromuscular disorders were more probably reported with anti-PD-1. Several pathogenic mechanisms, including neuronal damage by T cells and autoantibodies and\/or cytokine-mediated inflammation processes, have been hypothesized. However, the pathogenesis of these ICI-related complications is not completely understood. Considering the recent marketing authorizations of ICIs, further studies are strongly needed to monitor their neurologic safety profile.<\/jats:p>","DOI":"10.3389\/fonc.2022.824511","type":"journal-article","created":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T02:44:14Z","timestamp":1647312254000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Neurological Manifestations Related to Immune Checkpoint Inhibitors: Reverse Translational Research by Using the European Real-World Safety Data"],"prefix":"10.3389","volume":"12","author":[{"given":"Rosanna","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Stelitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fraenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"di Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liberata","family":"Sportiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concetta","family":"Rafaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Di Napoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Del Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological Toxicities Associated With Immune-Checkpoint Inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00084","article-title":"Successful Treatment of Myasthenia Gravis Following PD-1\/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma","volume":"9","author":"Werner","year":"2019","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer Immunotherapy Using Checkpoint Blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science (80-)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: Co-Inhibitory Receptors With Specialized Functions in Immune Regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune Checkpoint Inhibitors: Recent Progress and Potential Biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.005","article-title":"Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01167-0","article-title":"Camrelizumab: First Global Approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s11912-019-0851-x","article-title":"Novel Immunotherapy Combinations","volume":"21","author":"Bashir","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00090-z","article-title":"The Global Pipeline of Cell Therapies for Cancer","volume":"18","author":"Xin Yu","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel Immune Checkpoint Targets: Moving Beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12339","article-title":"Immune Checkpoint Inhibitors-Induced Neuromuscular Toxicity: From Pathogenesis to Treatment","volume":"24","author":"Psimaras","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/FONC.2021.814014","article-title":"Identification of Key Pathways and Genes Related to Immunotherapy Resistance of LUAD Based on WGCNA Analysis","volume":"11","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.3390\/cancers13081949","article-title":"Cancers Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC","volume":"13","author":"Dong","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102089","DOI":"10.1016\/J.CTRV.2020.102089","article-title":"Cellular Immunotherapy in Breast Cancer: The Quest for Consistent Biomarkers","volume":"90","author":"Venetis","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2174\/1871520621666210706144112","article-title":"Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology","volume":"21","author":"Criscitiello","year":"2021","journal-title":"Anticancer Agents Med Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00425","article-title":"Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System","volume":"10","author":"Mascolo","year":"2019","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13421","article-title":"Mechanisms of Checkpoint Inhibition Induced Adverse Events","volume":"200","author":"Urwyler","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4235","article-title":"Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review","volume":"25","author":"Myers","year":"2018","journal-title":"Curr Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12883-019-1416-1","article-title":"Pembrolizumab-Related Systemic Myositis Involving Ocular and Hindneck Muscles Resembling Myasthenic Gravis: A Case Report","volume":"19","author":"Kamo","year":"2019","journal-title":"BMC Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe Neurologic Complications of Immune Checkpoint Inhibitors: A Single-Center Review","volume":"265","author":"Mancone","year":"2018","journal-title":"J Neurol"},{"key":"B21","unstructured":"BlackmonJT\n            ViatorTM\n            ConryRM\n          Central Nervous System Toxicities of Anti-Cancer Immune Checkpoint Blockade2016"},{"key":"B22","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic Toxicity Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-01021-3","article-title":"PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports From the Eudravigilance Database","volume":"44","author":"di Mauro","year":"2021","journal-title":"Drug Saf"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/IJERPH19010413","article-title":"The Importance of Direct Patient Reporting of Adverse Drug Reactions in the Safety Monitoring Process","volume":"19","author":"Sienkiewicz","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/S40801-019-00174-7","article-title":"Severe Cutaneous Adverse Drug Reactions Associated With Allopurinol: An Analysis of Spontaneous Reporting System in Southern Italy","volume":"7","author":"Scavone","year":"2020","journal-title":"Drugs - Real World Outcomes"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/PH14070611","article-title":"Cardiac Events Potentially Associated to Remdesivir: An Analysis From the European Spontaneous Adverse Event Reporting System","volume":"14","author":"Rafaniello","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2020.00428","article-title":"Quinolones-Induced Musculoskeletal, Neurological, and Psychiatric Adrs: A Pharmacovigilance Study Based on Data From the Italian Spontaneous Reporting System","volume":"11","author":"Scavone","year":"2020","journal-title":"Front Pharmacol"},{"key":"B28","unstructured":"Meddra"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01086-8","article-title":"Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance","volume":"44","author":"Mascolo","year":"2021","journal-title":"Drug Saf"},{"key":"B30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe Relapse in a Multiple Sclerosis Patient Associated With Ipilimumab Treatment of Melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12961","article-title":"Myasthenic Crisis and Polymyositis Induced by One Dose of Nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia Gravis: An Emerging Toxicity of Immune Checkpoint Inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune Checkpoint-Mediated Myositis and Myasthenia Gravis: A Case Report and Review of Evaluation and Management","volume":"39","author":"Kang","year":"2018","journal-title":"Am J Otolaryngol - Head Neck Med Surg"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-Related Myasthenia Gravis With Myositis and Myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0106","article-title":"Myasthenia Gravis Induced by Avelumab","volume":"11","author":"Yuen","year":"2019","journal-title":"Immunotherapy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting Myasthenia Gravis, Myositis, and Polyneuropathy Induced by Ipilimumab and Nivolumab in a Patient With non-Small-Cell Lung Cancer: A Case Report and Literature Review","volume":"96","author":"Chen","year":"2017","journal-title":"Med (United States)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03514-8","article-title":"Neurological Adverse Effects Due to Programmed Death 1 (PD-1) Inhibitors","volume":"148","author":"Shi","year":"2020","journal-title":"J Neurooncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1758835918764628","DOI":"10.1177\/1758835918764628","article-title":"Clinical Assessment of Immune-Related Adverse Events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-1056","article-title":"An Immune-Related Gene Expression Signature Predicts Brain Metastasis in Lung Adenocarcinoma Patients After Surgery: Gene Expression Profile and Immunohistochemical Analyses","volume":"10","author":"Koh","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25643","article-title":"Clinical Variables and Primary Tumor Characteristics Predictive of the Development of Melanoma Brain Metastases and Post-Brain Metastases Survival","volume":"117","author":"Zakrzewski","year":"2011","journal-title":"Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2017.07.005","article-title":"Can Causality Assessment Fulfill the New European Definition of Adverse Drug Reaction? A Review of Methods Used in Spontaneous Reporting","volume":"123","author":"Mascolo","year":"2017","journal-title":"Pharmacol Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological Immune Related Adverse Events Associated With Nivolumab, Ipilimumab, and Pembrolizumab Therapy\u2014Review of the Literature and Future Outlook","volume":"8","author":"M\u00f6hn","year":"2019","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120542","article-title":"Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials","volume":"7","author":"Grassadonia","year":"2018","journal-title":"J Clin Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01931","article-title":"Sex Hormones Determine Immune Response","volume":"9","author":"Taneja","year":"2018","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1723\/2625.26992","article-title":"Gender Differences in Lung Cancer","volume":"2","author":"Vaval\u00e0","year":"2016","journal-title":"Ital J Gender-Specific Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.3390\/molecules24183214","article-title":"Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer Immunotherapy Efficacy and Patients\u2019 Sex: A Systematic Review and Meta-Analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30270-5","article-title":"Does a Patient\u2019s Sex Predict the Efficacy of Cancer Immunotherapy","volume":"19","author":"Abdel-Rahman","year":"2018","journal-title":"Lancet Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5904","article-title":"Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-Analysis","volume":"5","author":"Wallis","year":"2019","journal-title":"JAMA Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ensci.2018.11.023","article-title":"Concomitant Myasthenia Gravis, Myositis, Myocarditis and Polyneuropathy, Induced by Immune-Checkpoint Inhibitors: A Life\u2013Threatening Continuum of Neuromuscular and Cardiac Toxicity","volume":"14","author":"Rota","year":"2019","journal-title":"eNeurologicalSci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2021.756872","article-title":"Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/J.NBD.2022.105627","article-title":"Impact of Intestinal Disorders on Central and Peripheral Nervous System Diseases","volume":"165","author":"El-Hakim","year":"2022","journal-title":"Neurobiol Dis"},{"key":"B55","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/TNSCI-2020-0206","article-title":"Functional Roles of the Microbiota-Gut-Brain Axis in Alzheimer\u2019s Disease: Implications of Gut Microbiota-Targeted Therapy","volume":"12","author":"Zhong","year":"2021","journal-title":"Transl Neurosci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02254","article-title":"Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells","volume":"10","author":"Anderson","year":"2019","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.03.003","article-title":"Microbiome Transplantation and Modulation of Immune Related Adverse Events","volume":"8","author":"Smibert","year":"2019","journal-title":"EClinicalMedicine"},{"key":"B58","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/s0735-1097(20)30663-x","article-title":"Cardiovascular and Cerebrovascular Events Among Patients Receiving Immune Checkpoint Inhibitors","volume":"75","author":"Alvi","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.3390\/ijms21165774","article-title":"Molecular Sciences Immune-Driven Pathogenesis of Neurotoxicity After Exposure of Cancer Patients to Immune Checkpoint Inhibitors","volume":"21","author":"Vilari\u00f1o","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.184777","article-title":"Schiavo a Lo. A Case of Figurate Urticaria by Etanercept","volume":"7","author":"Sessa","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-018-0498-5","article-title":"Neuropsychiatric Clinical Manifestations in Elderly Patients Treated With Hydroxychloroquine: A Review Article","volume":"26","author":"Mascolo","year":"2018","journal-title":"Inflammopharmacology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDV623","article-title":"Management of Immune Checkpoint Blockade Dysimmune Toxicities: A Collaborative Position Paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.824511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T02:44:20Z","timestamp":1647312260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.824511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,15]]},"references-count":62,"alternative-id":["10.3389\/fonc.2022.824511"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.824511","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,15]]},"article-number":"824511"}}